Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6081859 | 0.81 | MTNR1A (0.42) | CA1CA2CA12CA7CA14 | |
| SCHEMBL6081951 | 0.81 | MTNR1A (0.48) | CA1CA2CA12CA7CA14 | |
| SCHEMBL8409849 | 0.79 | MTNR1A (0.66) | MTNR1AMTNR1B | |
| SCHEMBL6076582 | 0.78 | CA1 (0.41) | CA1CA2CA12CA7CA14 | |
| SCHEMBL6076018 | 0.78 | CA1 (0.41) | CA1CA2CA12CA7CA14 | |
| SCHEMBL6075588 | 0.78 | MTNR1A (0.72) | CA1CA2CA12CA7CA14 | |
| SCHEMBL8548336 | 0.77 | CA1 (0.51) | CA1CA2CA12CA7CA14 | |
| SCHEMBL6087427 | 0.75 | MTNR1A (0.38) | CA1CA2CA12CA7CA14 | |
| SCHEMBL6081459 | 0.74 | CA1 (0.38) | CA1CA2CA12CA7CA14 | |
| SCHEMBL6081321 | 0.73 | MTNR1A (0.50) | CA1CA2CA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7126012-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-24 | — | — | US | disclosed |
| US-7115752-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-03 | — | — | US | disclosed |
| US-20050124682-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-06-09 | — | — | US | disclosed |
| US-6872851-B1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20050059729-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059729-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | CA1 2119/4885CA2 3101/4885CA12 2142/4885 |
| US-20050124682-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | CA1 2119/4885CA2 3101/4885CA12 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.